Evidence map›Paper›PMID 42129815›Full record

ArticleJournal of nanobiotechnology2026

Asymmetric nanozymes improve cardiac purine catabolism and alleviate oxidative stress of myocardium to treat ischemic heart disease.

Yun Jiang, Hang Chen, Wei Chen, Liyun Zhu, Xiya Wang, Pingyuan Sun, Chanyuan Su, Renxiang Gui, Huiying Yang, Tao Yue and 8 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of nanobiotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Yun Jiang *Department of Burn and Plastic Surgery, Affiliated Hospital of Nantong University, Medical School of Nantong University, Nantong, 226000, China.
Hang Chen *Institute of Geriatrics, School of Life Sciences, Shanghai University, Affiliated Nantong Hospital of Shanghai University (The Sixth People's Hospital of Nantong), Shanghai University, Nantong, 226011, China.
Wei Chen *Department of Critical Care Medicine, Tongji Hospital, School of Medicine, Tongji University, Shanghai, 200065, China.
Liyun ZhuInstitute of Geriatrics, School of Life Sciences, Shanghai University, Affiliated Nantong Hospital of Shanghai University (The Sixth People's Hospital of Nantong), Shanghai University, Nantong, 226011, China.
Xiya WangSchool of Gongli Hospital Medical Technology, University of Shanghai for Science and Technology, Shanghai, 200093, China.
Pingyuan SunInstitute of Geriatrics, School of Life Sciences, Shanghai University, Affiliated Nantong Hospital of Shanghai University (The Sixth People's Hospital of Nantong), Shanghai University, Nantong, 226011, China.
Chanyuan SuDepartment of Cardiology, Heart Center of Fujian Province, Fujian Medical University Union Hospital, Fuzhou, 350001, Fujian, China.
Renxiang GuiInstitute of Geriatrics, School of Life Sciences, Shanghai University, Affiliated Nantong Hospital of Shanghai University (The Sixth People's Hospital of Nantong), Shanghai University, Nantong, 226011, China.
Huiying YangSchool of Mechatronic Engineering and Automation, Shanghai University, Shanghai, 200444, China.
Tao YueSchool of Mechatronic Engineering and Automation, Shanghai University, Shanghai, 200444, China.
Kunpeng WangSchool of Mechatronic Engineering and Automation, Shanghai University, Shanghai, 200444, China.
Pengyu YangSchool of Gongli Hospital Medical Technology, University of Shanghai for Science and Technology, Shanghai, 200093, China.
Lizhi DouSchool of Gongli Hospital Medical Technology, University of Shanghai for Science and Technology, Shanghai, 200093, China.
Linlin ZhaoDepartment of Neurology, Fourth Affiliated Hospital of Harbin Medical University, Harbin, 150001, Heilongjiang, China.
Emeli ChatterjeeCardiovascular Division of the Massachusetts General Hospital, Harvard Medical School, Boston, MA, 02114, USA.
Guoping LiCardiovascular Division of the Massachusetts General Hospital, Harvard Medical School, Boston, MA, 02114, USA.
Xuerui ChenInstitute of Geriatrics, School of Life Sciences, Shanghai University, Affiliated Nantong Hospital of Shanghai University (The Sixth People's Hospital of Nantong), Shanghai University, Nantong, 226011, China. chenxuerui@shu.edu.cn.
Jianle ChenDepartment of Cardiothoracic Surgery, Affiliated Hospital of Nantong University, Medical School of Nantong University, Nantong, 226001, China. jsshcjl@ntu.edu.cn.

Funding

National Natural Science Foundation of China 22373064National Natural Science Foundation of China 82300412
6 · The paper itself

Abstract

Ischemic heart disease (IHD) refers to a condition with myocardial ischemia, hypoxia, and even cardiomyocyte death due to coronary artery stenosis or occlusion. Energy metabolism gets disturbed by imbalanced ATP synthesis and degradation, while conversion of hypoxanthine to xanthine degraded from ATP synchronously provokes excessive reactive oxygen species (ROS). Metabolic disturbance and oxidative stress are pivotal features of IHD, both of which are associated with increased purine catabolizing enzyme activity of xanthine oxidoreductase (XOR). Here, we construct mushroom-like asymmetric nanozyme (CeAu MAN) through symmetry-breaking synthesis of ceria and gold nanoparticles, which function with XOR-inhibitory effects in cardiac purine metabolism. Mechanistically, superior superoxide dismutase (SOD)-like and catalase (CAT)-like activities of CeAu MAN reduce intracellular ROS levels and diminish oxidative stress-induced cardiomyocyte apoptosis. As revealed by metabolomics in conjunction with purine-related metabolites, CeAu MANs constrain purine degradation pathways by inhibiting metabolic conversion of xanthine into uric acid in the injured myocardium through a heterointerface-mediated affinity to XOR. We also demonstrated therapeutic efficacy of CeAu MANs in MI/RI mice including improved heart function, attenuated maladaptive remodeling, and reliable biocompatibility in three weeks. Symmetry-breaking mushroom-like CeAu MANs improve cardiac purine catabolism and spark an innovative paradigm in metabolic therapy of IHD.

Indexed as

Myocardial IschemiaMyocardiumOxidative StressPurinesAnimalsApoptosisGoldHumansMaleMetal NanoparticlesMiceMyocytes, CardiacReactive Oxygen SpeciesXanthine DehydrogenaseGoldPurinesReactive Oxygen SpeciesXanthine DehydrogenaseATP metabolismCardiac repairIschemic heart diseaseOxidative stressSymmetry-breaking structure

Identifiers

PMID42129815
PMCPMC13352700

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.